Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $267.40 +8.65%
Revenue Growth %: +15.3%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +15.3%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- Tilly's, Inc. (TLYS) Tops Q2 EPS by 10c, Beats on Revenue
- C3.ai (AI) Tops Q1 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
